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Abstract Salsolinol (1-methyl-6,7-dihydroxy-1,2,3,4-
tetrahydroisoquinoline) is a tetrahydroisoquinoline derivative
whose presence in humans was first detected in the urine of
Parkinsonian patients on L-DOPA (L-dihydroxyphenylalanine)
medication. Thus far, multiple hypotheses regarding its
physiological/pathophysiological roles have been proposed, es-
pecially related to Parkinson’s disease or alcohol addiction. The
aim of this review was to outline studies related to salsolinol,
with special focus on in vivo and in vitro experimental models.
To begin with, the chemical structure of salsolinol together with
its biochemical implications and the role in neurotransmission
are discussed. Numerous experimental studies are summarized
in tables and the most relevant ones are stressed. Finally, the
ability of salsolinol to cross the blood–brain barrier and its
possible double-faced neurobiological potential are reviewed.
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Introduction
Salsolinol (SAL) is a tetrahydroisoquinoline derivative whose
presence in humans was first detected in the urine of
Parkinsonian patients on L-DOPA (L-dihydroxyphenylalanine)
medication (Sandler et al. 1973). Almost side by side, salsolinol
was determined in the urine of healthy human volunteers at
higher concentrations than that in the urine of intoxicated alco-
holics (Collins et al. 1979) and in rat brains treated with ethanol
(Collins and Bigdeli 1975). Thus far, multiple hypotheses re-
garding its physiological/pathophysiological roles have been
proposed, especially regarding Parkinson’s disease (PD, 131
records, including 22 reviews in PubMed, April 2017, key-
words: BParkinson’s disease,^ BParkinson disease,^
BParkinson’s,^ Bsalsolinol^) or alcohol addiction (152 records,
including 14 reviews in PubMed, April 2017, keywords:
Bethanol,^ Balcohol,^ Bsalsolinol^).
Sa l so l ino l (1 -me thy l -6 ,7 -d ihyd roxy-1 ,2 ,3 ,4 -
tetrahydroisoquinoline) possesses an asymmetric center at C-1;
thus, it exists as R and S enantiomers as shown in Fig. 1.
Endogenously, non-enzymatic condensation of dopamine (3,4-
dihydroxyphenylethylamine, DA) with acetaldehyde yields a ra-
cemic mixture of enantiomers (Cohen and Collins 1970), while
stereoselective enzymatic synthesis from dopamine via (R)-
salsolinol synthase generates the (R)-enantiomer (Naoi et al.
1996; Chen et al. 2011). The existence of (R)-salsolinol synthase
has been proposed, but its existence may be doubtful because
neither has it been isolated and fully characterized nor has its
amino acid sequence been determined. Nonetheless, the levels
of (R)-salsolinol tend to be greater than those of (S)-salsolinol in
human brain tissue (Deng et al. 1997;Musshoff et al. 1999, 2000,
2003, 2005). Several research groups have quantified both enan-
tiomers in human and rat brain tissue (for a review, see Hipólito
et al. 2012), and their presence may indicate a predominance of
endogenous synthesis over exogenous accumulation (Musshoff
et al. 1999, 2000, 2003, 2005). However, the commonality of
salsolinol in many plant- and protein-derived food sources, such
as cheese, cocoa powder, bananas, flour, eggs, beer, milk, or fish
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Fig. 1 Metabolic pathways of dopamine and (R)-salsolinol in the brain (based on Naoi et al. 2002)
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(Riggin and Kissinger 1976; Riggin et al. 1976; Duncan and
Smythe 1982; Duncan et al. 1984; Collins et al. 1990; Deng
et al. 1997; examples are given in Table 2), cannot be neglected.
The main aim of this review was to outline the most rele-
vant studies related to salsolinol and focus on in vivo and
in vitro experimental models, its possible double-faced (neu-
rotoxic vs. neuroprotective) neurobiological potential and im-
ply its enigmatic role in the periphery.
Chemical Structure of Salsolinol and Its Biochemical
Implications
Salsolinol and MPTP
The concept of salsolinol contribution to the pathogenesis of idi-
opathic Parkinson’s disease has emerged from its chemical simi-
larity to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine,
Table 1). MPTP is a synthetic compound, still used in industry
as a chemical intermediate and is a selective dopaminergic neu-
rotoxin capable of causing parkinsonism in both humans and
animals (Langston et al. 1983; Chiueh et al. 1985; for review,
see Langston et al. 1987; Singer et al. 1987). However, MPTP
should not be considered an etiological factor for Parkinson’s
disease while salsolinol being both an endogenous and an envi-
ronmental compound seems to be a reasonable candidate. The
toxicity of MPTP is a result of monoamine oxidase type B
(MAO B)-dependent transformation to MPP+ ions (Bradbury
et al. 1986; Trevor et al. 1988; see Table 1). The MPP+ ions can
selectively accumulate in dopaminergic neurons due to the activ-
ity of the dopamine transporter (DAT) (Javitch et al. 1985), lead-
ing to inhibition of the oxidative phosphorylation at complex I of
the mitochondrial respiratory chain and reduction of ATP produc-
tion (Trevor et al. 1987; Singer et al. 1988). The presence of theN-
methyl group is crucial for MPTP toxicity (Bradbury et al. 1985).
Indeed, the N-methylation of salsolinol into N-methyl-
salsolinol by N-methyltransferase (in fact, by N-methyltrans-
ferases with different optimum pH values, pH 7.0 and 8.4)
was proven in vitro in human brain homogenates (Naoi et al.
1989) and in vivo in the rat brain (Maruyama et al. 1992). N-
methyl-salsolinol is supposed to be further oxidized into 1,2-
dimethyl-6,7-dihydroxyisoquinolinium ions (DMDHIQ+)
non-enzymatically by autoxidation (Maruyama et al. 1995)
or enzymatically by an oxidase sensitive to semicarbazide
(Naoi et al. 1995).
Salsolinol—the Condensation Product of Dopamine
with Acetaldehyde
It was hypothesized that, in the brain, the concentration of N-
methyl-(R)-salsolinol and DMDHIQ+ ions depends on the ac-
tivity of their synthesizing enzymes (Maruyama et al. 1992), but
the level of their precursor, (R)-salsolinol, should most likely
depend on the dopamine and acetaldehyde (or pyruvate to less
extent) concentration in the brain, regardless of how it is syn-
thesized, enzymatically or non-enzymatically. Thus, the follow-
ing questions, which have not been fully addressed yet, arise:
under what circumstances might dopamine (or an excess of
dopamine) lead to salsolinol production (and why) and is acet-
aldehyde produced locally in the brain or from the periphery?
Dopamine (DA), the product of L-DOPA, synthesized in-
directly from phenylalanine or directly from tyrosine, is stable
in synaptic vesicles. An excess amount of cytosolic DA is
easilymetabolized via monoamine oxidase (MAO) to produce
H2O2 and dihydroxyphenylacetic acid (DOPAC) or via
autooxidation to produce O2
− and reactive quinones. DA- or
L-DOPA-induced neurotoxicity mediated by the generation of
free radicals has been reported in damaged neurons both
in vitro and in vivo (Cadet and Brannock 1998; Ogawa et al.
1993; Asanuma et al. 2003; Chen et al. 2008; Miyazaki and
Asanuma 2008). DA is also broken down by catechol-O-
methyl transferase and aldehyde dehydrogenase. Together,
different breakdown pathways exist, but the main end-
product is homovanillic acid (HVA), which has no clearly
elucidated biological activity (Eisenhofer et al. 2004).
Different cellular regulatory mechanisms and protective bio-
chemical pathways, such as the glutathione pathway, are crit-
ical to maintain cytosolic dopamine homeostasis and prevent
dopamine-induced neurotoxicity. However, the detrimental
effects of dopamine could be exaggerated because of genetic
defects or environmental challenges (Chen et al. 2008). For
example, parkin-deficient mice showed increased extracellu-
lar dopamine levels (measured quantitatively by in vivo mi-
crodialysis), likely due to an increase in dopamine release
from nigral neurons (Goldberg et al. 2003) while striatal levels
of dopamine and its major metabolites (measured by high-
performance liquid chromatography in homogenized tissue)
were similar between parkin-deficient and wild-type mice.
Mutations in the human parkin gene are responsible for auto-
somal recessive juvenile parkinsonism, a heritable disease that
resembles Parkinson’s disease (Goldberg et al. 2003; Perez
and Palmiter 2005). Although parkin-deficient mice do not
recapitulate signs central to the disease, they might provide
important insights into the normal physiological role of parkin
in dopamine regulation and nigrostriatal function (Goldberg
et al. 2003). Moreover, parkin knockdown in differentiated
dopaminergic PC12 cells elevated cellular oxidative stress,
endogenous salsolinol and N-methyl-salsolinol levels, which
were responsible for the higher cell mortality upon exposure
to exogenous H2O2. The results suggest the potential role of
salsolinol and its metabolites in parkin knockdown-induced
cell vulnerability (Su et al. 2013).
On the other hand, the presence of acetaldehyde is usu-
ally associated with alcohol ingestion; however, in fact,
rapid metabolism of acetaldehyde by the liver maintains
its blood levels extremely low. Even if the blood
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acetaldehyde levels were significant, either because of ge-
netic variation in alcohol-metabolizing enzymes or certain
enzyme inhibitors, acetaldehyde is hardly able to cross the
blood–brain barrier (Tabakoff et al. 1976; Westscott et al.
1980; Sippel 1974; Deitrich et al. 2006). However, it has
been demonstrated that acetaldehyde can be formed in the
brain from ethanol (Aragon et al. 1992; Gill et al. 1992). The
intensity of ethanol oxidation is rather low but may be much
higher in the specific structures known for their increased
catalase activity (Zimatkin and Lindros 1996). The produc-
tion of acetaldehyde by catalase is limited by the availability
of hydrogen peroxide, and acetaldehyde is metabolized to
acetate nearly as quickly as it is formed, by aldehyde
dehydrogenase (ALDH). ALDH is localized mainly in mi-
tochondria (while catalase in peroxisomes) and thus acetal-
dehyde can interact with other cellular elements before be-
ing further metabolized to acetate (Deitrich et al. 2006).
Acetaldehyde can either directly bind to proteins (Jennett
et al. 1987; McKinnon et al. 1987; Nakamura et al. 2003),
nucleic acids (Wang et al. 2010) and phospholipids (Kenney
1982, 1984; Trudell et al. 1990, 1991) or condense with
dopamine and serotonin to form tetrahydroisoquinolines
and tetrahydro-beta-carbolines (Deitrich and Erwin 1980;
De i t r i c h e t a l . 2 006 ) . Ma l ond i a l d ehyde o r 4 -
hydroxynonenal produced because of lipid peroxidation
could also inhibit the activity of ALDH (Mark et al. 1997;
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Meyer et al. 2004), which might result in increased levels of
acetaldehyde (Deitrich et al. 2006) and might further pro-
mote the synthesis of salsolinol in dopaminergic cells (Kim
et al. 2016). Increased exogenous salsolinol levels will sub-
sequently elevate the cellular oxidative stress level via re-
leasing reactive oxygen species from mitochondria
(Wanpen et al. 2004, see Table 4 for details) and might
further potentiate the possible neurotoxic effect of dopa-
mine and L-DOPA.
The direct precursor of dopamine, L-DOPA, can be synthe-
sized either indirectly from the essential amino acid phenylala-
nine or directly from the non-essential amino acid tyrosine read-
ily available in food, by tyrosine hydroxylase (which action can
be inhibited by salsolinol). L-DOPA is converted into dopamine
by the aromatic L-amino acid decarboxylase (also known as
DOPA decarboxylase), with pyridoxal phosphate as the cofac-
tor. Dopamine is found inmany types of food, but it cannot cross
the blood–brain barrier; therefore, it must be synthesized locally
in the brain. Dopamine can be further used as a precursor in the
synthesis of the norepinephrine and epinephrine or can be bro-
ken down into inactive metabolites by monoamine oxidase, cat-
echol-O-methyl transferase, COMT (both enzymes can be
inhibited by salsolinol) and aldehyde dehydrogenase. (R)-
Salsolinol synthase possibly catalyzes the reaction of dopamine
with acetaldehyde or pyruvic acid to produce (R)-salsolinol or
(R)-salsolinol 1-carboxylic acid. Both (R)- and (S)-salsolinol
can be also formed non-enzymatically by the Pictet–Spengler
reaction of dopamine with acetaldehyde. N-Methyltransferase
catalyzes the N-methylation of (R)-salsolinol, but not that of
(S)-salsolinol, into N-methyl-(R)-salsolinol. The oxidation of
N-methyl-(R)-salsolinol can be either non-enzymatic
(autooxidation) or enzymatic by an oxidase (sensitive to
semicarbazide) and leads to the formation of 1,2-dimethyl-6,7-
dihydroxyisoquinolinium ions (DMDHIQ+). Both (R)- and (S)-
salsolinol can be metabolized by COMT to form 6-
methoxy-(R/S)-salsolinol and 7-methoxy-(R/S)-salsolinol. It re-
mains unknown under what circumstances dopaminemight lead
to salsolinol production and whether acetaldehyde comes from
local production in the brain or from the periphery. It is also
uncertain whether exogenous salsolinol (delivered from food)
can cross the blood–brain barrier.
The endogenous synthesis of salsolinol, although relatively
straightforward, requires appropriate conditions to be main-
tained. Thus, it seems reasonable to hypothesize that increased
salsolinol levels might be rather a consequence of dysregulat-
ed enzymatic pathways due to neurodegeneration, genetic mu-
tations, or exogenous inhibitors. Indeed, the peripheral and
central catecholamine system acts as the first responder to
environmental stimuli. Kocur (2016) reported that the highest
levels of endogenous salsolinol in mouse brain striatum ho-
mogenates resulted from the intraperitoneal administration of
50 mg/kg ethanol and 1 mg/kg L-DOPAwith the combination
of MAO (pargyline) and COMT (tolcapone) inhibitors.
Endogenous Salsolinol and Its Metabolites in Human
and Rodent Brain Tissue and Biological Fluids
In the normal human brain, salsolinol (Sjöquist et al. 1981)
and N-methylated salsolinol (Niwa et al. 1993) have been
identified by microdialysis, and the (R)-enantiomers of both
salsolinol and N-methyl-salsolinol were found to be present
(Deng et al. 1995). In fact, both (R)-salsolinol and (S)-
salsolinol tend to be present at higher concentrations in areas
with increased dopamine synthesis and turnover such as the
ventral midbrain and striatum (DeCuypere et al. 2008). The
levels of (R)-salsolinol tend to decrease in the caudate, puta-
men, and substantia nigra according to age (Maruyama et al.
1997). A negative correlation was confirmed between the age
and level of N-methyl-(R)-salsolinol in the human striatum.
The level of a dopamine metabolite, homovanillic acid
(HVA), or the ratio of HVA/dopamine, an indicator of dopa-
mine turnover, did not correlate with the levels of catechol
isoquinolines in the human brain (Naoi et al. 2004).
For many years, mostly due to analytical methods, it was
thought that (R)-salsolinol should be the only enantiomer
present in human brain tissue. Some of the analytical difficul-
ties of salsolinol quantification have been recently solved be-
cause of the development of more sensitive methods for its
analysis (DeCuypere et al. 2008; Rojkovicova et al. 2008;
Starkey et al. 2006), hugely improving the detection limits
and chiral resolution. However, the lack of agreement among
the results reported by different authors (for example
DeCuypere et al. 2008 compared with Musshoff et al. 2000,
2003, 2005) is clearly noticeable—for example, 28.6 ng/
g ± 18.3 (Musshoff et al. 2000) vs. 204.79 ng/g ± 21.91
(DeCuypere et al. 2008) for (R)-salsolinol and 18.5 ng/
g ± 14.1 (Musshoff et al. 2000) vs. 213.19 ng/g ± 25.83
(DeCuypere et al. 2008) for (S)-salsolinol in human substantia
nigra. According to Hipólito et al. (2012), these differences
could be due to differences in the post-mortem processing of
the samples—shorter than 6 h in the DeCuypere study vs. up
to 144 h in the Musshoff study. It should also be mentioned
that Musshoff et al. (2000) applied gas chromatography/mass
spectrometry (GC/MS), while DeCuypere et al. (2008) ap-
plied high-performance liquid chromatography with electro-
chemical detection (HPLC-EC) and liquid chromatography
with tandem mass spectroscopy (LC-MS/MS) for (R/S)-
salsolinol analysis. Hipólito et al. (2012) elegantly summa-
rized the basal salsolinol levels in different brain areas in
healthy humans and alcoholics (see Hipólito et al. 2012).
A low concentration of the racemic form of salsolinol was
also detected in normal human cerebrospinal fluid (Moser and
Kömpf 1992) and urine (Dostert et al. 1989). Parkinsonian
patients treated with L-DOPA and chronic alcoholics showed
a significant elevation of the salsolinol concentration in cere-
brospinal fluid and urine (Cohen and Collins 1970; Sandler
et al. 1973, Collins et al. 1979; Moser and Kömpf 1992), but
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no difference was shown between de novo Parkinsonian pa-
tients and controls (Müller et al. 1999). However, the level of
N-methyl-(R)-salsolinol in cerebrospinal fluid from untreated
patients with PD was significantly higher than that in controls,
especially at the early stage of the disease (Maruyama et al.
1996). The activity of a neutral N-methyltransferase was
found to increase significantly in lymphocytes isolated from
PD patients (100.2 ± 81.8 pmol/min/mg of protein) compared
that in controls (18.9 ± 15.0 pmol/min/mg of protein) (Naoi
et al. 1998). Furthermore, significantly lower levels of (R)-
salsolinol, (S)-salsolinol, N-methyl-(R)-salsolinol, and N-
methyl-(S)-salsolinol were found in the caudate nuclei of PD
patients compared with those in the normal human brain
(DeCuypere et al. 2008).
In rodents, salsolinol concentrations tended to be higher in
brain areas rich in dopamine (similarly to humans), and there
was a tendency toward an excess of (R)-salsolinol in brain areas
with a lower dopamine concentration (Hipólito et al. 2012).
In vivo, after the rat striatum was perfused with exogenous
(R)-salsolinol, N-methyl-(R)-salsolinol was found to occur se-
lectively in the substantia nigra, hypothalamus, and hippocam-
pus, possibly suggesting that the distribution should not solely
depend on DA but also on the activity of the synthesizing
enzymes. Indeed, the N-methyltransferase activity was found
to be higher in the rat nigro-striatum than in other brain regions
(Maruyama et al. 1992). After the rat striatum was perfused
with exogenous N-methyl-(R)-salsolinol, N-methyl-(R)-
salsolinol, and DMDHIQ+ ions were accumulated especially
in the striatum and, to a lesser extent, in the substantia nigra.
Dopamine and noradrenaline levels were reduced in the
substantia nigra and in the striatum, whereas serotonin and its
metabolites were not affected. In vitro experiments showed that
the binding of DMDHIQ+ ions to melanin in the substantia
nigra was enhanced by Fe(II) whereas Fe(III) enhanced the
release of the ions from melanin, and released DMDHIQ+ ions
could further cause inhibition of the mitochondrial enzymes
and depletion of ATP from dopaminergic neurons (Naoi et al.
1996). At the same time, the anti-oxidant and pro-oxidant prop-
erties of intracellular dopamine should be noted, especially with
regard to their role in the transformation of intracellular iron.
Dopamine can form various complexes with both Fe(II) and
Fe(III) over a range of pH, further leading to the generation of
reactive oxygen species (Sun et al. 2016).
Role of Salsolinol in Neurotransmission
Binding Sites for Salsolinol
Selective binding of salsolinol was confirmed not only in
brain dopaminergic structures such as the striatum but also
in the pituitary gland, cortex, and hypothalamus (Homicskó
et al. 2003). Salsolinol produced agonistic effects at
muscarinic receptors as well as at α- and β-adrenoceptors
(Rodger et al. 1979, see Tables 3 and 4 for details). It produced
concentration-dependent inhibition of the vasoconstrictor re-
sponse to electrical stimulation of the periarterial sympathetic
nerves but did not inhibit the vasoconstrictor response to ex-
ogenous norepinephrine. The inhibitory effect of salsolinol on
neurotransmission was antagonized by yohimbine but not by
sulpiride or propranolol. The mono-O-methylated metabolites
of salsolinol antagonized the inhibition of neurotransmission
produced by dopamine. Salsolinol could act as an agonist on
prejunctional α-adrenergic receptors and 6-O-methyl
salsolinol and 7-O-methyl salsolinol could act as antagonists
on dopaminergic receptors (Nelson and Steinsland 1983).
Salsolinol antagonized the behavioral action of L-DOPA and
apomorphine (Ginos and Doroski 1979; Antkiewicz-Michaluk
et al. 2000a, b). It suppressed dopaminergic transmission by
acting on the agonistic sites of dopaminergic D1 and D3 recep-
tors different from neuroleptic binding sites (Antkiewicz-
Michaluk et al. 2000a, b; Vetulani et al. 2001). Salsolinol did
not produce any extrapyramidal symptoms and did not poten-
tiate haloperidol-induced catalepsy in rats (Vetulani et al. 2003).
Several studies have also shown that salsolinol could acti-
vate the mesolimbic system. In vitro and in vivo studies (see
Tables 3 and 4 for examples) have suggested that salsolinol
should exert its action on neuron excitability through a mech-
anism involving opioid neurotransmission. Salsolinol might
act like the endogenous opioid encephalin. In silico analysis
predicts a morphine-like interaction between (R)- and (S)-
salsolinol with the μ-opioid receptor, and (S)-salsolinol is be-
lieved to be a more potent agonist (Matsuzawa et al. 2000;
Hipólito et al. 2010, 2011, 2012; Xie et al. 2012; Berríos-
Cárcamo et al. 2017). However, there is no direct pharmaco-
logical evidence.
[3H]-salsolinol also bound specifically to homogenates of
the anterior lobe and neuro-intermediate lobe obtained from
lactating rats. (R)-salsolinol was present in high concentration
in the neuro-intermediate lobe as well as in median eminence
extracts of males, and intact and ovariectomized female rats. It
was hypothesized that salsolinol could be synthesized in situ
and could play a role in the regulation of pituitary prolactin
(PRL) secretion, without an effect on the secretion of other
pituitary hormones (Tóth et al. 2001, 2002). Salsolinol might
regulate the neurotransmission of neuroendocrine dopaminer-
gic neurons by an altered intracellular or intraterminal synthe-
sis and/or distribution of dopamine, thus acting as an endog-
enous prolactin-releasing factor, especially during lactation
(Homicskó et al. 2003; Radnai et al. 2004).
Catecholamine Transporters
Salsolinol is also regarded as an inhibitor of catecholamine
uptake in rat brain synaptosomes because it caused the release
of catecholamines stored in the rat brain (Heikkila et al. 1971).
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In confluent monolayers of human neuroblastoma SH-SY5Y
cells, salsolinol at concentrations below 100 μM stimulated
catecholamine uptake. Conversely, at concentrations above
100 μM, salsolinol inhibited the uptake of [3H]-noradrenaline
and [3H]-dopamine (Willets et al. 1995, see Table 4 for details).
Takahashi et al. did not find any accumulation of salsolinol
in human SH-SY5Y cells mediated by DAT (dopamine trans-
porter) (Takahashi et al. 1994), while Matsubara et al. demon-
strated DAT-mediated influx of (R)-salsolinol into rat striatal
synaptosomes (Matsubara et al. 1998). However, the affinity
of isoquinoline derivatives (especially (R)-salsolinol) for the
dopamine transporter compared with MPP+ was proven to be
rather low. The intermolecular distance between the N-atom
and centrinoid of the benzene or catechol ring was suggested
as being an important factor in dopamine uptake inhibition
(McNaught et al. 1996a). Storch et al. (2002) again addressed
the importance of the dopamine transporter molecule for se-
lective dopaminergic toxicity in non-neuronal and neuronal
heterologous expression systems of the DAT gene (human
embryonic kidney HEK-293 cells and mouse neuroblastoma
Neuro-2A cells). The authors concluded that, besides MPP+,
only the 2[N]-methylated salsolinol derivatives, such as N-
methyl-salsolinol, showed enhanced cytotoxicity in both
DAT-expressing cell lines (Storch et al. 2002).
According to Taubert et al. (2007), in the dopaminergic
regions of the substantia nigra, organic cation transporter 2
(OCT2) co-localized with DAT and tyrosine hydroxylase
(TH). Cyclo(his-pro) and salsolinol were identified as selec-
tive endogenous substrates of the organic cation transporter
OCT2. The overlay of energy minimized the conformations
(MM2 computation, Chem3D Pro software) of native cyclo(L-
his-L-pro) (enol tautomer, endo-conformation), and R-
salsolinol uncovered close structural similarities, suggesting
a planar ring system, an electrophilic center and a nucleophilic
moiety with H-donor properties at a constant distance (of
6.560.3 A ) as key properties of an OCT2-specifc substrate
(Taubert et al. 2007).
Monoamine Oxidase
Nakahara et al. (1994) reported that, following 1 mM (R)-
salsolinol perfusion, the dialysate level of 5-HT in the rat
striatum markedly increased from non-detectable levels to
4259.2 ± 617.5 nM, while the DA levels increased from
3.4 ± 0.9 to 206.0 ± 56.5 nM. These effects were dose-
related to (R)-salsolinol (1 μM to 1 mM) and were confirmed
also in three other brain regions (the substantia nigra, the hip-
pocampus and the hypothalamus). The repetitive perfusion
with 1 mM (R)-salsolinol into the striatum induced the repro-
ducible response of 5-HT and DA (Nakahara et al. 1994). The
analyses of monoamine metabolites in the microdialysate in
the rat striatum indicated that salsolinol should inhibit MAO
and catechol-O-methyltransferase (COMT) activities in situ.
Indeed, the levels of 3,4-dihydroxyphenylacetic acid
(DOPAC), homovanillic acid (HVA) and, most significantly,
5-hydroxyindolacetic acid (5-HIAA) were reduced (Giovine
et al. 1976; Maruyama et al. 1993; Nakahara et al. 1994).
The inhibition of MAO (monoamine: oxygen oxidoreduc-
tase EC 1.4.3.4) by salsolinol was first reported by Yamanaka
(1971). Salsolinol (racemic mixture) inhibited MAO activity
in the rat brainstem and liver homogenates, and the inhibition
was competitive to serotonin, a substrate of MAO type A, and
non-competitive to benzylamine, a substrate of MAO type B
(Meyerson et al. 1976). In vitro, (R)-salsolinol inhibited MAO
Amore potently than the (S)-enantiomer (Minami et al. 1993).
The oxidized DMDHIQ+ is the most potent inhibitor of MAO
A, followed by N-methyl-(R)-salsolinol, (R)-salsolinol, and
N-methylnorsalsolinol (Naoi et al. 1994). The presence of
hydroxyl groups at the sixth and seventh positions and substi-
tution of a hydrogen group at the first position with a methyl
or dihydroxybenzyl group are required for the inhibition,
whereas the absence of a methyl group or presence of a car-
boxyl group at the first position, in addition to a methyl group,
depletes the inhibitory activity. The structure-activity relation-
ship of isoquinoline derivatives was reported in detail by
Bembenek et al. (1990) and Thull et al. (1995). The results
were confirmed in vivo (Maruyama et al. 1993).
Catechol-O-Methyltransferase
Salsolinol serves as a substrate for catechol-O-methyltransfer-
ase (S-adenosyl-L-methionine: catechol O-methyltransferase,
EC 2.1.1.6, COMT) and as a competitive inhibitor (Giovine
et al. 1976). Salsolinol was O-methylated primarily in vivo at
the 7-position, to form salsoline—l-methyl-7-methoxy-6-hy-
droxy-l,2,3,4-tetrahydroisoquinoline (Collins and Origitano
1983)—whereas catecholamines are O-methylated in vivo at
the 3-position. The O-methylation of catecholamines causes
the elimination of their physiological properties, whereas
salsoline can still be accumulated and stored in catecholamine
nerve terminals of the brain where it might act as false neuro-
transmitters (Cohen and Mytilineou 1982).
Hötzl and Thomas (1997) reported that O-methylation by
pig brain-soluble and membrane-bound catechol-O-methyl-
transferase yielded almost equivalent Km and Vmax values
for both enantiomers. Their results also indicated thatO-meth-
ylation was stereoselective regarding O-methylation patterns:
(S)-salsolinol yielded almost equivalent amounts of the two
possible 6- and 7-methyl ethers, whereas 7-O-methyl deriva-
tive was 88% of the product when the (R)-enantiomer was
methylated (Hötzl and Thomas 1997, see Table 4 for details).
Tyrosine Hydroxylase
Exogenous salsolinol also inhibited a rate-limiting enzyme in
dopamine synthesis—tyrosine hydroxylase (tyrosine
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tetrahydropteridine: oxygen oxidoreductase (3-hydroxylat-
ing), EC 1.14.16.2, TH)—prepared from rat brain. The inhi-
bition constant, Ki, for salsolinol was 14 μM, and the inhibi-
tion was competitive to a cofactor, 6,7-dimethyl-5,6,7,8-
tetrahydropterin (Weiner and Collins 1978). The asymmetric
center of salsolinol at C-1 plays an important role in changing
the enzyme affinity toward L-tyrosine. (R)-Salsolinol deleted
the allostery of TH to the biopterin and reduced the activity
more markedly than its (S)-enantiomer. The authors suggested
that, under physiological conditions, such a conformational
change may alter the regulation of DOPA biosynthesis in the
brain (Minami et al. 1992).
In vitro, exogenous salsolinol inhibited TH activity in the
nanomolar range by binding to both the high and low affinity
dopamine-binding sites. Salsolinol produced the same level of
inhibition as dopamine when TH was non-phosphorylated.
However, it produced 3.7-fold greater inhibition of Ser40-
phosphorylated TH than dopamine by competing more
strongly with tetrahydrobiopterin. Salsolinol’s potent inhibi-
tion of TH phosphorylation might prevent TH from being
fully activated to synthesize dopamine (Briggs et al. 2013).
L-Tryptophan Hydroxylase
Exogenous salsolinol and its derivatives inhibited a rate-
limiting enzyme in indoleamine synthesis—tryptophan hy-
droxylase prepared from the rat brain (L-tryptophan,
tetrahydropteridine: oxygen oxidoreductase (3-hydroxylat-
ing), EC 1.14,16,2, TPH (L-tryptophan hydroxylase)). The
inhibition was non-competitive in terms of either the
biopterine cofactor or substrate L-tryptophan. 1,2[N]-
Dimethyl-6,7-dihydroxyisoquinolinium (DMDHIQ+) ion
was an extremely potent inhibitor (Matsubara et al. 1994).
The (R)-and (S)-enantiomers of salsolinol were also found
to inhibit the activity of tryptophan hydroxylase prepared from
serotonin-producing murine mastocytoma P-815 cells.
Inhibition was found to be non-competitive with the substrate
L-tryptophan. Tryptophan hydroxylase is composed of two
elements with different kinetic properties in terms of the co-
factor (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin, and these
two elements were inhibited by salsolinol competitively and
non-competitively. Thus, salsolinol enantiomers might be nat-
urally occurring inhibitors of indoleamine metabolism (Ota
et al. 1992).
Other Enzymes
Salsolinol exerted a considerable effect on the balance be-
tween dopamine and acetylcholine (ACh). (R)-salsolinol and
its derivative N-methyl-(R)-salsolinol led to concentration-
dependent decreases in the activity of acetylcholinesterase
(EC 3.1.1.7, AChE). ACh concentrations in the striatum treat-
ed with (R)-salsolinol or N-methyl-(R)-salsolinol were
increased. N-methyl-(R)-salsolinol caused a significant de-
crease in dopamine concentrations, and (R)-salsolinol reduced
the concentrations of dopamine metabolites in the striatum
(Zhu et al. 2008, see Table 3 for details).
Salsolinol competitively inhibited the activity of
debrisoquine 4-monooxygenase in rat liver microsomes, dem-
onstrating that salsolinol has a molecular shape corresponding
to the active site of CYP2D1 (Iwahashi et al. 1993, see Table 4
for details).
It was also reported that, when human ceruloplasmin (EC
1.16.3.1, hCP) was incubated with salsolinol, it caused protein
aggregation and enzyme inactivation. Reactive oxygen spe-
cies scavengers and copper chelators inhibited salsolinol-
mediated hCP modification and inactivation (Kim et al.
2016, see Table 4 for details). Thus far, decreased hCP ferrox-
idase activity in cerebrospinal fluid (Boll et al. 1999, 2008)
and serum (Tórsdóttir et al. 1999; Bharucha et al. 2008;
Martínez-Hernández et al. 2011) from idiopathic PD patients
has been reported.
Clinical Implications
It can be clearly summarized that salsolinol might actively
modulate dopaminergic and serotonergic neurotransmission
in the brain; thus, it might influence L-DOPA therapy. It was
reported by Wąsik et al. (2015) that the acute injection of
exogenous salsolinol enhanced the L-DOPA-induced eleva-
tion of dopamine release, whereas the chronic administration
of salsolinol completely blocked the L-DOPA-induced eleva-
tion of dopamine release in the rat striatum. These data dem-
onstrated that the chronic administration of exogenous
salsolinol significantly impaired the response of dopaminergic
neurons to L-DOPA (Wąsik et al. 2015).
Krygowska-Wajs et al. reported that the concentration of
endogenous salsolinol was related to the degree of Parkinson’s
disease and cannot be affected by L-DOPA treatment in the
cerebrospinal fluid of patients with different degrees of par-
kinsonism, treated or not with L-DOPA. By contrast, HVA and
3-O-methyldopa were significantly elevated in patients receiv-
ing L-DOPA but did not correlate with the severity of parkin-
sonism (Krygowska-Wajs et al. 1997).
Salsolinol in Experimental Models
The literature on salsolinol’s molecular interactions and its
role in neurotransmission is truly multifocal. The presence of
two enantiomers and their origin, either endogenous or
exogenous, is complex. However, most of the experimental
data, both in vivo and in vitro, refer to exogenous salsolinol
hydrochloride applied as a racemic mixture. Quintanilla et al.
(2014, 2016) not only chirally separated a commercially avail-
able (RS)-salsolinol but also purified it from isosalsolinol
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(isosalsolinol is a by product of non-enzymatical Pictet–
Spengler condensation). However, in some studies, salsolinol
was synthetized according to different protocols, and its purity
was not assessed. Such variations in methodological ap-
proaches present a potential barrier to make a comprehensive
summary.
In Vivo Studies
The in vivo models related to salsolinol are summarized in
Table 3. Rodent models, especially Wistar and Sprague–
Dawley rats, have been the most useful to study the selective
occurrence of salsolinol, its metabolism and physiological
function, especially in the central nervous system. Salsolinol
is regarded as a modulator of dopaminergic neurotransmis-
sion, but its exact biological role remains unclear. Thus far,
animal modeling has been mainly has been advancing as fol-
lows: (1) salsolinol as a modulator of catecholaminergic neu-
rotransmission in the nigrostriatal pathway and possibly as an
etiological factor in Parkinson’s disease, (2) salsolinol as a
neuromodulator in the mesolimbic pathway related to rein-
forcing effects of alcohol consumption, and (3) salsolinol as
a prolactin-releasing factor in the tuberoinfundibular pathway.
Animal Models—the Peripheral Role of Salsolinol?
Mravec et al. (2004) suggested that salsolinol may act at the
level of sympathetic ganglia because the intraperitoneal appli-
cation of salsolinol effectively reduced both plasma epineph-
rine and norepinephrine levels during stressful situations in
rats (Bodnár et al. 2004). Therefore, it was hypothesized that
salsolinol might participate in the physiological regulation of
the peripheral sympathoadrenal system activity and prevent
the over-activation of this system during episodes of acute
stress (Mravec 2006). Further research in this matter is also
needed.
Unfortunately, most animal studies related to salsolinol
have been dealing with its role in the brain, and little attention
has been paid to its possible peripheral activity (see Table 3),
especially in the enteric nervous system (ENS), which seems
quite logical. Catecholamines, such as epinephrine and nor-
epinephrine, are well known to modulate gastrointestinal mo-
tility (Li et al. 2004). However, the gut also contains dopa-
mine, and the DA-to-NE ratio in the ENS is higher in the
bowel than in other sympathetic targets, and contains a high
concentration of the specific DA metabolite 3,4-
dihydrioxyphenylacetic acid (Eaker et al. 1988). DA is an
enteric neurotransmitter as well. Enteric dopaminergic neu-
rons, which express tyrosine hydroxylase and the dopamine
transporter (DAT) but lack dopamine hydroxylase, have been
identified in the mouse, guinea pig (Li et al. 2004) and human
(Anlauf et al. 2003). The potential of DA (and salsolinol) to
influence the gut remains to be fully explored. Until now, it
was only shown that exogenous salsolinol induced myenteric
neuronal cell (the nitrergic inhibitory motor neurons) death
(Kurnik et al. 2015) and altered gastrointestinal motility
(Banach et al. 2005, 2006) in Wistar rats. It has never been
established if salsolinol could be endogenously formed and
further metabolized in the enteric nervous system.
In Vitro Studies
In vitro models related to salsolinol are summarized in
Table 4. The human dopaminergic neuroblastoma SH-SY5Y
cell line model has been applied in most of the studies.
Salsolinol is attributed to pro-apoptotic activity regardless of
the in vitro model. Its toxicity is mostly due to: oxidative
damage (formation and release of hydroxyl free radicals)
and inactivation of Cu,Zn-superoxide dismutase, with the sub-
sequent disruption of cellular respiration as well as up-
regulation of pro-apoptotic and down-regulation of anti-
apoptotic proteins. Salsolinol also caused neurofilament
(NF-L) aggregation and the loss of glutamate, lysine and pro-
line residues proportional to the concentration and incubation
time, as well as induced strand scission and damage in DNA
(Table 4). However, all in vitro studies should be always
interpreted with caution and verified in vivo.
Molecular Mechanisms Related to Salsolinol
Morikawa et al. (1998) reported that salsolinol inhibited most
potently mitochondrial complex I activity. Oxidation of N-
methylated derivatives into N-methylisoquinolinium ion aug-
mented the potency to inhibit mitochondrial respiration and
complex I (Morikawa et al. 1998). Wanpen et al. (2007) con-
firmed that mitochondrial complex I activity was significantly
decreased, and reactive oxygen species were increased when
SH-SY5Y cells were treated with racemic salsolinol. The
treatment decreased the levels of the anti-apoptotic protein
bcl-2 and increased pro-apoptotic protein bax, while enhanc-
ing the release of cytochrome c from mitochondria (Wanpen
et al. 2007). Storch et al. (2000) concluded that salsolinol was
toxic to human dopaminergic neuroblastoma SH-SY5Y cells
by blocking the cellular energy supply via the inhibition of
mitochondrial complex II activity (succinate-Q reductase) but
not that of complex I. The rapid decrease in the intracellular
level of ATP and ATP/ADP ratio of intact cells incubated with
salsolinol was dose- and time-dependent (Storch et al. 2000).
Exposure of neuroblastoma SH-SY5Y cells to salsolinol
also resulted in a significant decrease in thapsigargin or
carbachol-mediated Ca(2+) influx. SH-SY5Y cells treated
with salsolinol showed a reduction in transient receptor poten-
tial channel 1 (TRPC1) protein levels. Overexpression of the
TRPC1 gene and increased TRPC1 protein levels protected
SH-SY5Y cells against salsolinol-mediated cytotoxicity.
TRPC1 overexpression also inhibited cytochrome c release
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and decreased the levels of anti-apoptotic bax protein required
for apoptosis (Bollimuntha et al. 2006).
N-methyl-(R)-salsolinol induced apoptosis in dopamine
neurons, as shown in the rat model, and the mechanism of cell
death was studied in SH-SY5Y cells (Takahashi et al. 1997;
Maruyama et al. 2001, 2002; Akao et al. 1999, Naoi et al.
2002). N-methyl-(R)-salsolinol was the most potent to induce
DNA damage, whereas N-methyl-(S)-salsolinol and salsolinol
were less cytotoxic. Apoptosis was initiated by mitochondrial
permeability transition as shown by the collapse in the mem-
brane potential, followed mainly by the release of cytochrome
c, activation of caspase 3 and final fragmentation of nucleo-
somal DNA (Maruyama et al. 2001). The enantio-specificity
to induce apoptosis was confirmed in isolated mitochondria
(Akao et al. 2002). Racemic salsolinol was also cytotoxic to
dopaminergic neurons, but a quite different mechanism seems
to function in the induction of cell death, mostly due to the
production of reactive oxygen species by autoxidation, which
resulted in metabolic compromise and necrotic cell death
(Storch et al. 2000).
In another in vitro model—the dopaminergic neuronal cell
line RCSN-3—salsolinol was found to decrease survival in a
concentration-dependent manner. The levels of catalase and
glutathione peroxidase mRNA decreased when RCSN-3 cells
were treated with salsolinol (Martinez-Alvarado et al. 2001,
see Table 4 for details). Neural stem cells (NSCs) cultured
from the rat fetal brain challenged with racemic salsolinol
elicited a concentration- and time-dependent cell death via
the loss of mitochondrial viability. Significant mitochondrial
impairment was initiated at 10 μM salsolinol and suggested
apoptosis (Shukla et al. 2013, see Table 4 for details).
Salsolinol was cytotoxic to rat pheochromocytoma (PC12)
cells (Jung and Surh 2001; Kim et al. 2001). Cells exposed
to both salsolinol and Cu(II) exhibited higher levels of intra-
cellular reactive oxygen species than those treated with
salsolinol alone. These results suggest that copper accelerates
the redox cycling of salsolinol, leading to massive production
of reactive oxygen species, which can divert the salsolinol-
induced cell death to necrosis (Kim et al. 1997, 2001).
Salsolinol andN-methyl-salsolinol were detected in pheochro-
mocytoma (PC12) cells overexpressing α-synuclein com-
pared with normal PC12 cells and worsened α-synuclein-
induced mitochondrial damage (Zhang et al. 2013).
Salolinol and its metabolites impair mitochondrial function
in vitro, although the precise mechanisms underlying its tox-
icity remain poorly understood.
Salsolinol and the Blood–Brain Barrier
Regarding the determination of the biological potential of
salsolinol, an obvious question arises as to whether there is a
relationship between salsolinol in the periphery and that in the
central nervous system (whether salsolinol can cross the
blood–brain barrier)?
Sjöquist andMagnuson (1980) reported that acute intraper-
itoneal administration of salsolinol to rats resulted in levels of
1–2 nmol/g in the striatum and limbic forebrain after 2 h,
whereas the corresponding liver values were about
550 nmol/g, while control animals showedmuch lower values
(Sjöquist and Magnuson 1980; Table 3). However, Origitano
et al. (1981) suggested that salsolinol should not be able to
cross the blood–brain barrier because single intraperitoneal
administration of salsolinol did not result in measurable brain
salsolinol or mono-O-methyl-salsolinol levels. He also sug-
gested that salsolinol present in the central nervous system
of rats during ethanol intoxication should not be of peripheral
origin, and salsolinol present in the cerebrospinal fluid of al-
coholics during acute detoxification should be formed central-
ly (Origitano et al. 1981; Table 3). This was further confirmed
by Székács using single intravenous administration of 3H–
salsolinol and who suggested that the target of salsolinol’s
action should be at the periphery related to the transport of
norepinephrine in the sympathetic nerve terminals (Székács
et al. 2007a; Table 3). The data from other recent rodent stud-
ies indicate that salsolinol was indeed not able to reach the
rat’s brain after a single intraperitoneal administration. Liquid
chromatography-tandem mass spectrometry, a sensitive and
reliable analytical method (with a detection limit of 2 ng/
ml), in combination with in vivo microdialysis was applied
fo r the de t e rmina t ion o f sa l so l ino l ( and o the r
terahydroisoquinolines) in rat brain dialysates (Song et al.
2006a, b; Table 3).
According to Lee et al. (2010), in the long term, salsolinol
from different dietary sources (examples are given in Table 2)
Table 2 Some examples of (R)- and (S)-salsolinol levels in fruits and
vegetables obtained in the USA in August 2007, according to DeCuypere
(2010). Solid-phase extraction (SPE) was performed on all samples prior
to liquid chromatography–mass with tandem mass spectrometry (LC-
MS/MS) analysis. Values are expressed in ng/g of wet weight. SAL
salsolinol
Source (R)SAL (ng/g wet weight) (S)SAL (ng/g wet weight)
Mushroom 3572.80 +/− 13.44 3557.40 +/− 17.48
Banana 2717.50 +/− 9.81 2870.87 +/− 10.95
Leaf letuce 2615.23 +/− 42.35 2660.49 +/− 33.55
Celery 1372.85 +/− 15.60 1382.01 +/− 12.03
Grape 951.62 +/− 11.71 980.84 +/− 12.96
Sweet potato 295.23 +/− 5.87 286.80 +/− 8.49
Green bean 195.17 +/− 9.31 215.58 +/− 6.89
Pear 34.09 +/− 1.44 35.18 +/− 9.74
Peach 31.85 +/− 9.51 39.46 +/− 5.54
Cherry 16.73 +/− 3.44 12.03 +/− 4.77
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should be the major contributor to its plasma levels, both in
humans and rats. Despite the increases observed in plasma
salsolinol or dopamine levels, their levels were not changed
in the striatum or nucleus accumbens. The enantiomeric
(R/S)-salsolinol and dopamine compositions were determined
by a highly specific and reliable method, high-performance
liquid chromatography coupled with electrospray ionization-
tandemmass spectrometry, with detection limits set at 2 pg for
salsolinol isomers and 20 pg for dopamine (Lee et al. 2010).
However, according to Quintanilla et al. (2014), exogenous
salsolinol produced conditioned place preference and increased
locomotor activity, either injected intracerebrally or intraperito-
neally. Following the intraperitoneal administration of salsolinol,
thismoleculewas detected in vivo in the neostriatum and reached
an estimated concentration of 100 nM in the dialysate
(Quintanilla et al. 2014; Table 3). Several authors have also re-
ported that systemically administered salsolinol can alter labora-
tory animal behavior (Naoi et al. 1996; Antkiewicz-Michaluk
et al. 2000a; Matsuzawa et al. 2000; Vetulani et al. 2001), indi-
rectly suggesting that salsolinol could cross the blood–brain bar-
rier. It was clearly demonstrated that other tetrahydroisoquinoline
derivatives (Fig. 2), such as 1,2,3,4-tetrahydroisoquinoline,
5,6,7,8-tetrahydroisoquinoline, N-methyl-salsolinol, N-methyl-
norsalsolinol, 1-methyl-1,2,3,4-tetrahydroisoquinoline, and 1-
benzyl-1,2,3,4-tetrahydroisoquinoline, could also cross the
blood–brain barrier (Makino et al. 1988; Thumen et al. 2002;
Song et al. 2006a, b; Lorenc-Koci et al. 2008). Regarding the
physiology of the blood–brain barrier, the most plausible mech-
anism for N-methyl-salsolinol and N-methyl-norsalsolinol to
cross this barrier should be passive diffusion; thus, salsolinol,
with a similar lipophilicity, might be able to diffuse passively
through the membranes of vascular cells to enter the brain.
However, until now, no study has demonstrated a mechanism
through which exogenous salsolinol might cross it. It was suc-
cessfully demonstrated by Panula et al. (1979) that intraperitone-
ally injected fluorescent dihydroisoquinoline was trapped in rat
brain endothelial cells if administered at a low dose, whereas the
injection of a high dose led to leakage to the neuropil in the
cerebral cortex and striatum and accumulation in brain cells
(Panula et al. 1979). According to Melzig and Zipper (1993),
the neurotoxic effect of salsolinol could be caused by damaging
endothelial cells associated with a disturbance in the blood–brain
barrier (Melzig and Zipper 1993; Table 4).
Thus, there are also multiple factors that should be consid-
ered when trying to compare different studies to determine the
ability of salsolinol to cross the blood–brain barrier: the dif-
ferent commercial sources or methods of their laboratory syn-
thesis, the applied doses and enantiomers as well as routes of
administration, and the animal species and strains used in the
experiments. Some of these aspects are further summarized in
Tables 3 and 4. For example, the pharmacokinetics of intrave-
nous (i.v.) and intraperitoneal (i.p.) injections differ from each
other—during i.v. injection, the maximum concentration in
the blood is reached almost at once and immediately begins
to fall; however, after i.p. injection, most of the drug is
absorbed by the mesentery veins and then gathered into the
portal vein of the liver, similar to oral gavage. While intra-
cerebroventricular drug administration is a method that by-
passes the blood–brain barrier and fundamentally differs from
the systemic drug administration in terms of pharmacokinetic
characteristics to determine the brain tissue concentrations
(Cook et al. 2009). However, further research is needed to
clarify various aspects of complex salsolinol (among others
tetrahydroisoquinoline derivatives) pharmacokinetics.
Dose-Related Neurobiological Activity of Salsolinol
Maruyama et al. (1995), for the first time, concluded that
salsolinol and its derivatives might possess both neurotoxic
and neuroprotective activity. Exogenous (R)-salsolinol
(40 μM), the isoquinolinium ion (200 μM), and N-
methyl-(R)-salsolinol (200 μM) reduced in vivo free radical
formation and reduced dopamine catabolism. (R)-Salsolinol
and the isoquinolinium ion reduced in vitro hydroxyl radical
production from dopamine autoxidation. However, on the oth-
er hand, N-methyl-(R)-salsolinol (40 μM) increased the hy-
droxyl radical level in the striatum, and the free radical pro-
duction by its autoxidation was confirmed in vitro. N-
Methyl-(R)-salsolinol affected neither in vivo dopamine ca-
tabolism nor in vitro production of hydroxyl radicals from
dopamine (Maruyama et al. 1995). Biphasic effects, either
neuroprotective or neurotoxic, of exogenous salsolinol ap-
plied as a racemic mixture were confirmed by Możdżeń
et al. (2015) in vitro. In rat hippocampal cell cultures, the
lower investigated dose of salsolinol (50 and 100 μM) was
diminished, while its highest dose (500 μM) potentiated the
glutamic acid effect on caspase-3 activity. Similar effects were
observed for lactate dehydrogenase (LDH) release. In mouse
striatum cultures, both the investigated doses of salsolinol (50
and 500 μM) revealed the neuroprotective activity. Authors
concluded that salsolinol under physiological conditions
could not be neurotoxic (Możdżeń et al. 2015). Our own pre-
liminary, yet unpublished, in vitro results also suggested that
the biological action of exogenous salsolinol applied as a ra-
cemic mixture, either neurotoxic or neuroprotective, might be
indeed dose and time dependent.
Thus, it seems reasonable to wonder whether alcohol con-
sumption should lead to an increased risk of the development
of Parkinson’s disease According to Lee et al. (2010), no
significant changes in the salsolinol plasma levels or its enan-
tiomeric distribution after acute or chronic ethanol exposure of
healthy humans were noted, suggesting that salsolinol may
not be a biomarker for ethanol drinking (Lee et al. 2010).
Additionally, unfortunately, there is no agreement within the
epidemiological studies, and the question regarding whether
500 Neurotox Res (2018) 33:485–514
ethanol consumption (together with smoking and coffee con-
sumption) might be biologically protective or toxic remains a
matter of debate. For example, Bettiol et al. recently reported
that studies with a prospective design did not support any
association between total alcohol intake and PD risk (with
two studies finding an increased risk with a moderate alcohol
consumption), and the case-control studies were more likely
to find protective effects of alcohol on PD risk (Bettiol et al.
2015). Ward et al. highlighted neurochemical pathways relat-
ed to monoamine oxidases and nitric oxide synthase as those
involved in the protective effects of nicotine and ethanol in
preventing the development or delay in the progression of
Parkinson’s disease (Ward et al. 2008).
Tetrahydroisoquinoline derivatives, which are abundant in
nature (Rommelspacher and Susilo 1985), can be divided into
catechol and non-catechol structures depending on the biogen-
ic amines participating in a condensation (so-called Pictet–
Spengler) reaction. The catechol (1,2 –dihydroxybenzene)
moiety occurs widely in nature and is usually associated with
anti-oxidant properties. The relatively high anti-oxidant activ-
ity of catechol can be explained by the high electron-donating
effect of one hydroxyl group to the other (Heijnen et al. 2011,
2002). Salsolinol possesses a catechol moiety; thus, at least
theoretically, it might limit excitotoxicity and oxidative stress,
which might have clinical implications. However, 1-methyl-
1,2,3,4-tetrahydroisoquinoline (a non-catechol derivative) is
regarded as one of the most potent neuroprotectants among
tetrahydroisoquinolines in the brain. Its neuroprotective effect
did not induce the development of tolerance after chronic ad-
ministration and might restore the function of dopamine neu-
rons, suggesting its clinical relevance (Wąsik et al. 2016;
Vetulani and Antkiewicz-Michaluk 2012).
Tetrahydroisoquinoline derivatives, which can mostly be
either synthesized endogenously and/or delivered exogenous-
ly, can predominantly alter central dopaminergic pathways.
Thus, their physiological/pathophysiological role should not
be ignored. Multiple factors, such as the dose, stereoisomer-
ism, local bioavailability, local biogenic amine metabolism or
even genetic heritage, may determine their biological, possi-
bly opposing, activity.
6. Conclusions
The neuromodulatory role of salsolinol is indeed still
poorly understood. In general, the available experimental
data include many single-center findings for which repli-
cation by other researchers has not been reported and
Fig. 2 Tetrahydroisoquinolines
capable of crossing the blood–
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Neurotox Res (2018) 33:485–514 507
508 Neurotox Res (2018) 33:485–514
might be partly considered plausible. The most scrupulous
attention should be paid to the role of the salsolinol’s
stereoisomers. Whether salsolinol present in the brain
comes solely from local production or, by contrast, there
is a significant contribution from the non-cerebral sites or
from dietary sources should be established at the earliest
convenience.
Salsolinol co-localizes with dopamine-rich regions in
the brain. The same should apply for the peripheral tis-
sues, therefore boosting further advances in this field.
Because the enteric nervous system and gut microbiota
are the major sources of serotonin and dopamine in the
human body (Martinucci et al. 2015), the results might be
of clinical relevance not only in terms of prodromal
Parkinson’s disease but also gastrointestinal and gut-
brain axis disorders.
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